S564 ESTRO 35 2016 _____________________________________________________________________________________________________ pN1 stage, 190 pts with pT1-2 N2 while 100 pts with pT1/2 pN3 stage. Hystological subtype was luminal A ( lA=Er+/ Pr+ , Her neg G1-G2) in 164 pts; luminal B ( lB= Er+/Pr+, Her2 neg G3) in 170 pts; triple negative (TN= Er-Pr-Her2 neg) in 166 pts. Mean age was 65 yrs (range: 40-72 yrs). Patients were treated with chemotherapy according to prognostic features. All patients

more »

... ed whole breast radiotherapy witha a totale dose of 50 Gy + 10 Gy boost and 48-50 Gy on supraclavicular fossa. In case of medial tumors, the internal mammary chain was included. Kaplan-Meyer and paired t-test were used for statistical analysis. Results: The 5-year LRR and DR were obtained with a median of 6.3 years. The 5-year LRR was 1.9% in lA, 2.8 % in l B , 2.1% in TN ( p= .72). The 5-year DR was in lA 2%, lB 4.5%, 8 % in TN (p<.001) According to nodal status LRR was 1.7% in N1, 2.3% in N2 and 3.8% in N3 status (p= .005). The 5-year DR in N1 lA was 2.4 %, for lB was 3%, for TN was 3.5% ( p= .82) while in N2 lA it was 3 %,for lB was 5% and for TN it was 7.3% (p= .06); for N3 lA was 3.5%, for lB was 4.8%, for TN was 8.5%; overall DR of pN1 versus pN2/N3 was statistically significant (p= .02). On multivariate analyses high risk of LRR was related to T size (T>2 cm), presence of lymphovascular invasion, lobular hystology; high risk of DR was observed for N> 4 nodes, presence of ECE, Ki 67> 30% and age <50 years. Conclusion: : In this analysis triple negative breast cancer patients with pN1 seem to benefit by nodal radiation, but further studies are necessary EP-1185 Male breast cancer -outcome with adjuvant treatment B. Yadav 1